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The human transcriptome comprises a complex network of coding and non-coding RNAs implicated in a myriad of 
biological functions. Non-coding RNAs exhibit highly organised spatial and temporal expression patterns and are 
emerging as critical regulators of differentiation, homeostasis and pathological states, including in the cardiovascular 
system. This review defines the current knowledge gaps, unmet methodological needs and describes the challenges 
in dissecting and understanding the role and regulation of the non-coding transcriptome in cardiovascular disease. 
These challenges include poor annotation of the non-coding genome, determination of the cellular distribution of 
transcripts, assessment of the role of RNA processing and identification of cell-type specific changes in cardiovascular 
physiology and disease. We highlight similarities and differences in the hurdles associated with the analysis of the non-
coding and protein-coding transcriptomes. In addition, we discuss how the lack of consensus and absence of 
standardised methods affect reproducibility of data. These shortcomings should be defeated in order to make 
significant scientific progress and foster the development of clinically applicable non-coding RNA-based therapeutic 
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The completion of the human genome project in 2003 – an international joint public and private effort – is a date that 
will go down in history.1–3 Sequencing of all 46 chromosomes in the human genome revealed that we possess less than 
25 % of the predicted 100,000 protein-coding genes, a surprisingly similar number of protein-coding genes to that in 
the nematode worm.  
We now know that the human transcriptome is much more complex than previously thought. The advent of deep 
sequencing tools of the last 15 years has revealed a complex network of at least 10,000 long non-coding RNAs, encoded 
in a myriad of genomic contexts.4  
Non-coding RNAs are functional RNA molecules that lack protein-coding potential. Only a subset have so far been 
characterised, many exhibit high spatial and temporal expression patterns and are emerging as key regulators of 
differentiation, development, homeostasis and disease pathology, including in cardiovascular disease (CVD).  
Delineating the transcriptome changes in cardiac cell types and defining their regulation in disease-remodelling could 
not only enable us to further understand the cellular and molecular processes underlying pathology, but also provides 
the opportunity to select new, specific and more effective therapeutic targets to treat CVD.  
This review describes the challenges in dissecting and understanding transcriptome remodelling in CVD, focusing on 
non-coding genes. We will then discuss strategies being implemented to overcome these confounding factors. Finally, 
we review hurdles yet to overcome to improve reproducibility of data, convincingly delineate the cellular and 
molecular processes underlying cardiovascular pathology and catalyse translational impact.  
MicroRNAs (miRNAs) are 21-23 nt long short, single-stranded non-coding RNAs involved in post-transcriptional 
regulation of gene expression through binding to complementary sites predominantly in the 3’ untranslated regions 
(UTR) of pre-messenger RNA (mRNA, protein-coding).5 This binding event represses translation of the mRNA, often 
targeting it for degradation. At least 60 % of protein-coding genes are miRNA targets. Each miRNA can negatively 
regulate a number of different mRNAs and each of the miRNA-regulated protein-coding genes can be targeted by a 
number of miRNAs. This pleiotropic property of miRNAs has its advantages and disadvantages with regards to 
therapeutic potential. Complex diseases, including CVD, are most commonly multi-factorial and multi-genic, a 
consequence of multiple genetic and non-genetic factors. A miRNA often targets a number of mRNAs that converge 
on common biological pathways and processes. A large number of miRNA are dysregulated in CVD, in the heart or 
blood, identified through pre-clinical and translational studies.6 
MiRNA therapy has gained a lot of attention due to its specific targetability using chemically-modified antisense 
technology, enabled by the inherent complementary base-pairing properties of nucleic acids. Whilst a handful of 
antisense therapies have been approved to date by the U.S. Food and Drug Administration (FDA) targeting messenger 
RNAs no miRNA drugs have thus far made it onto the market. Contributing to the low rate of translation to the clinic 
is a lack of consensus methodologies and experimental approaches. Pre-clinical work in large animal models have 
preceded clinical trials, which are currently ongoing. 
Another facet of miRNA research in biomedical science is as circulating predictive, diagnostic and prognostic 
biomarkers of disease. Blood, plasma, serum and other biological fluids such as urine and tear drops have been found 
to be rich in RNA, either through release into the circulation from necrotic or apoptotic cells or having been actively 
secreted in microvesicles such as exosomes.7  
Long non-coding RNAs (lncRNAs) are defined as transcribed non protein-coding RNA molecules longer than 200 nt in 
length. LncRNA genes can overlap protein-coding genes, be located in an antisense orientation to protein-coding 
genes, intronic or intergenic (also known as long intervening noncoding RNAs (lincRNAs).8 In general, lncRNAs are less 
well conserved than protein-coding genes and exhibit a greater degree of temporal expression patterns and cell-type 
specificity. Their biological functions are as heterogeneous and widespread as proteins. LncRNAs are emerging as key 










Among lncRNAs, enhancer RNAs (eRNAs) describe a family of non-coding transcripts generated from enhancer regions 
of annotated genes that have a cis-regulatory role in transcription. Enhancer RNAs have been identified as regulators 
in cardiomyocyte(CM) differentiation development and homeostasis as well as being altered in response to 
pathological stimuli. 9–11 
A further recently discovered class of non-coding RNAs are the circular RNAs (circRNAs). CircRNAs are single-stranded 
and created by back splicing of 3’-5’ linear coding or non-coding RNAs, forming covalently closed loops.12 Originally 
thought to be a result of mis-splicing, circRNAs are now emerging as a major class of regulatory RNA molecules in 
disease and development. More than 30,000 circRNAs are now described in the human genome and diverse biological 
functions described and predicted including microRNA sponging and sequestration and protein binding affecting their 
stability.13 
CircRNAs are being examined not only for their intracellular activity but also as stable and specific circulating 
biomarkers reflecting cardiac dysfunction and pathology. The stability of circRNAs in the circulation exceed that of 
linear RNAs and their diagnostic value for CVD has started to be evaluated.14,15 
We are now aware that a significant number of lncRNAs and unannotated transcripts originally defined as purely non-
coding have short, translated open reading frames (sORFs).16 A number of strategies, including conservation analysis, 
has revealed micropeptides with important functional roles in biological processes. Accordingly, a recent sophisticated 
high-throughput examination of the ‘translatome’ in the healthy and diseased human heart by ribosome profiling 
revealed a vast number of potentially translated sORFs, including within 77 lincRNAs and 64 antisense transcripts.17 
Validation and biological relevance of these translatable regions remains to be elucidated.   
2. RNA sources and RNA integrity  
Whilst some aspects of CVD can be modelled in animals, due to our lack of understanding along with practicalities, 
biological differences and multi-factorial aetiologies, human CVD can never be perfectly emulated in pre-clinical 
models. Thus, to confirm the translational potential of findings in cellular and animal studies, human specimen can be 
used to show conservation of transcriptome analyses.  
Human specimens used in CVD research include, but are not limited to, liquid biopsies such blood, plasma, serum, 
buffy coat, isolated blood cells and solid tissues, such as cardiac biopsies, explanted cardiac tissue from heart 
transplant patients and hearts extracted from cadavers of victims of sudden death (so-called ‘donor’ hearts). 
Guidelines for standardised sample collection and storage are not well established, which leads to variability in the 
quality of RNA available.  
Isolation of good quality, intact RNA is required for techniques used for RNA and gene expression analysis including 
RTqPCR, RNA-sequencing (RNA-seq) and northern blotting. RNA integrity can be assessed qualitatively by running on 
a denaturing gel (e.g. with formaldehyde) and stained with a nucleic acid stain such as ethidium bromide. Intact RNA 
will give sharp, clean 28S and 18S ribosomal RNA (rRNA) bands, with the 28S approximately twice as intense as the 
18S band. Degraded RNA will lack these sharp rRNA bands with a 2:1 ratio and have a smear-like appearance. A faint 
smear may appear between 1 – 2 kb, containing other RNAs such as mRNAs and lncRNAs. With the knowledge that at 
least 80 % of the total cellular RNA is rRNA, RNA integrity can additionally be assessed with the knowledge of the mass 
of total RNA loaded and the rRNA bands compared against an RNA ladder of known marker size and mass. Elementary 
variations of this method have been devised to avoid the use of hazardous denaturing substances and improve 
resolution.18,19 Whilst gels offer a fast and simple means to assess RNA integrity with basic equipment used in 
molecular biology, even the latest nucleic acid gel imaging technologies and analysis tools are considered semi-
quantitative at best.  
The gold standard for assessing RNA integrity is the 2100 Bioanalyzer (Agilent). This device provides an automated 
electrophoresis strategy using microfluidics technology for RNA integrity analysis based on the relative rRNA species 
intensity. A range of microfluidics chips are available for different concentrations of RNA sample, with as little as 50 
pg required by the Pico RNA analysis products. The 2100 Bioanalyzer calculates an RNA Integrity Number (RIN), which 










and 18S ratio as well as any RNA species detected between the 18S and smaller 5S band. An alternative to the 2100 
Bioanalyzer, also by Agilent, is the Tapestation, which also uses capillary electrophoresis but requires slightly higher 
volumes and concentrations of RNA (at least 2 ul of ≥ 5ng/ul).  
Of note, these methods to assess RNA integrity are based on ribosomal RNAs. This is not suitable for assessing the 
quality of nuclear RNA or polyA RNA preparations, which are depleted of rRNA. Some semi-quantitative methodologies 
have been suggested for assessment of polyA RNA samples.21 
There is a lack of consensus regarding the minimal RIN value that should be used for accurate execution of RNA 
analysis. Moreover, different techniques for RNA analysis may be able to withstand different RNA integrity thresholds 
to be accurate and reproducible. For example, cDNA library synthesis requires initial RNA degradation into fragments 
either through heating or enzymatic digestion. Many researchers and next generation sequencing (NGS) technology 
companies and facilities arbitrarily state a minimum RIN value of 7 or 8 for deep RNA-sequencing. In the context of 
clinical samples in translational cardiovascular research, this minimum RIN is often unrealistic, with the example of 
fluid biopsies remaining on the bench at room temperature while the cardiologist tends to the patient.  
In the context of transcriptome analysis, a number of confounding factors can affect the outcome of research findings. 
In particular, the quality and integrity of RNA, determined by a number of pre-analytical variables along with sampling 
and storage methods.22 Table 1 provides an overview of confounding factors and pre-analytical variables affecting RNA 
integrity and outcomes of gene expression analysis.  
The post-mortem interval (PMI) is a primary confounding factor affecting quality and integrity of subsequently isolated 
biological material, such as DNA and RNA.   
Firstly, at ambient temperatures, RNA is highly labile and RNase enzymes remain catalytically active, naturally causing 
a decrease in RNA integrity with increased PMI. Evidence also suggests that not all RNAs are created equal, some being 
more susceptible to degradation.31 
Secondly, one could envisage stress-associated gene programmes, such as those induced by hypoxia, to be activated 
in the early PMI period. These two main influences can greatly affect the outcome of transcriptome analysis in CVD.  
For extraction of tissues from sudden death victims, the exact PMI is not always easy to determine and will inevitably 
not be consistent between samples. This is a common means by which tissues from ‘healthy/control’ individuals are 
collected. PMI in this case is usually determined by a pathologist based on physical observations of the corpse such as 
body temperature and rigor mortis. What’s more, heart tissue collected during procedures involved in treatment and 
investigation of cardiovascular disease, such as endomyocardial biopsies, valve replacements or heart transplants, is 
handled very differently, generally placed into cardioplegic solution followed by appropriate and rapid storage.  
Significantly, an analysis of GTEx (Genotype-Tissue Expression project) tissues and expression data of different human 
tissues with PMIs ranging from 1 to 27 hours and good quality RNA-seq data is available. A systematic analysis showed 
that cardiac and skeletal muscle displayed the greatest influence of PMI on the transcriptome, with over 850 genes 
significantly differentially expressed depending on PMI.23  
Comparing the transcriptome profiles between diseased and healthy heart samples, the vastly different and 
heterogeneous PMIs and handling protocols will influence the findings. In addition, there are no published guidelines 
set by standardisation bodies or networks of experts presenting consensus procedures in sample attainment, handling 
or storage. A first step to improve reproducibility should be a detailed description of sample harvesting and handling 
in all scientific publications, information that is often missing. 
The effect of the pre-processing time, as well as RNA integrity on the global depth of RNA-seq and on the outcome of 
gene expression analysis, was evaluated in only two studies of human peripheral blood mononuclear cells and human 
tissue (human placental samples).32,33 RNA integrity notably affected the results of gene expression analysis.  
The European Commission has acknowledged a need for international unity in governance and coordination of clinical 
biobanks.34 Clinical biobanks need to adhere to minimum information requirements as set out in the Minimum 










In conclusion, careful and correct collection, storage and sharing of information on pre-clinical variables as well as RNA 
integrity, evaluated by the gold standard RIN value, will enable consideration of these elements in translational 
cardiovascular research. These factors can then be incorporated as covariables in analysis platforms to identify 
independent gene expression changes. 
3. Cell-type specific versus whole tissue transcriptomic changes  
The heart is a highly heterogeneous organ, composed of at least six major cell types. The relative composition of the 
mammalian heart is a debated area but it is generally accepted that CMs, cardiac fibroblasts (CFs) and endothelial cells 
(ECs) are the dominant cell types.36,37 Other minor cell types include smooth muscle cells, pericytes and macrophages. 
Relative cell type composition changes through development, ageing and disease, with proliferation of most cell types 
occurring during mammalian development and growth. Conversely, ageing and disease are characterised by CM 
hypertrophy, attrition and apoptosis, by CF hyperproliferation and transformation into myofibroblasts and by 
intramyocardial infiltration of immune cells. Figure 1 depicts the composition of the adult heart and how different cell 
types are typically altered in response to chronic pathological stimuli.  
Alike, the vasculature is composed of smooth muscle cells, ECs, pericytes as well as a significant layer of connective 
tissue and elastic fibres. Remodelling of the vessel bed composition, cellular biology, morphology and structure occurs 
in injury and atherosclerosis.38 
Considering all the aforementioned factors and substantial remodelling of cardiac cellular composition in disease, 
transcriptomic data from whole heart tissue is not representative for a true comparison of changes within a particular 
cell type and makes translating bulk molecular changes to biological function, difficult. The resulting data sets 
represent only composite changes across the constituent cell types for that sample, often diluting changes that are of 
relevance in cellular and functional remodelling.  
A number of established protocols exist for isolation of CMs, CFs, ECs and immune cells from fresh heart tissue from 
animals and humans. These methods are centred around enzymatic digestion, often involving specialist equipment 
such as Langendorff apparatus for lengthy periods of aortic and coronary perfusion. Achieving high quality, high purity 
and consistent cell preparations proves variable between protocols, different laboratories as well as between species, 
samples and experimental conditions. 
One further significant caveat to isolation and separation of different cell types by enzymatic digestion is that fresh 
tissue is required, which needs to be maintained in cardioplegic solution since the point of extraction. Not only in some 
cases is access to fresh tissue impractical, such as in the case of biobanked human material, but the time of the 
preparations undertaken at ambient temperatures and conditions are conducive to DNA synthesis, transcription, RNA 
degradation as well as epigenetic modifier activity during the preparation time.39 
Furthermore, as previously indicated, anti-coagulants such as heparin administered during extraction of the heart as 
well as anti-thrombotic medication in patients, have been shown to interfere with cDNA synthesis reactions used in 
RT-qPCR or RNA-seq library preparations.26 
Variations on these methods for fresh CM and CF isolation have been developed with the aim of optimizing purity, 
cellular integrity and minimizing the need for anti-coagulants and complex apparatus, including through direct needle 
perfusion of the extracted heart ex vivo.40,41 
All confounding factors and circumstances considered, further approaches have been formulated to obtain cell type-
specific gene expression or epigenomic information. Whilst intact living cells can only be isolated from fresh cardiac 
tissue, nuclei can be extracted from frozen tissue. Fluorescence immunolabelling of cell type-specific nuclear antigens 
followed by flow cytometry enables collection of cell type-specific DNA and nuclear RNA. Examples include the use of 
pericentriolar material-1 (PCM-1), nuclear retained phospholamban or troponin T for CM nuclear isolation.42–45 A 
further benefit of this approach is that all steps can be performed at ice-cold temperatures and with addition of 
inhibitors of RNA Pol II and epigenetic mediators, such as sodium butyrate to suppress histone deacetylase activity, 










It should be noted that nuclear transcriptome data gives a different readout to cellular or bulk tissue RNA analysis. 
Firstly, 90 % of the total RNA in the cell is in the cytoplasm as mature processed RNA species. The nucleus is home to 
pre-processed RNA such as pre-mRNA, pri- and pre-miRNAs and nascent lncRNA transcripts. In addition, nuclear 
localised RNA species, such as lncRNAs, will be overly represented in the nucleus. Nuclear content gives a readout of 
more of the nascent transcription rates whereas cellular RNA is reflective of additional post-transcriptional regulation 
such as miRNA mechanisms and mRNA stability.46,47 Provided a pure nuclear population is isolated, transcripts from 
the 37 mitochondrial encoded genes will also be depleted. That said, direct comparison of results of global tissue or 
cellular vs nuclear RNA in a variety of models and species found strong correlations between the data sets from 
different origins.48 
One further approach to deducing the relative contribution of cell types in big transcriptomic data from bulk tissue 
or a mixed cell population is through bioinformatic deconvolution using established knowledge drawn from gene 
expression profiles of the individual composing cell types. One such example of where this strategy is employed very 
effectively is with whole blood specimen, where gene expression profiles of blood cell types - predominantly white 
blood cells – and sub-types are well described.49 An example of one such pipeline that has been developed for this 
purpose is Decon2.50 
Major advantages of this strategy include minimization of confounding factors involved in tissue separation and 
specific cell or nuclear isolation and sequencing, with the resulting data representing the relative cell population and 
tissue transcriptome close to that in vivo, provided appropriate extraction and storage of the biospecimen.  
That said, published examples of where bioinformatical deconvolution in this manner has been successfully employed 
in cardiovascular tissues are lacking. One probable reason for this is that transcriptional dysregulation is commonly 
seen in the context of disease, with cells of the cardiovascular system ectopically expressing genes atypical of their 
differentiated cell state. For example, CMs have been shown to express extracellular matrix protein in pro-fibrotic 
conditions and as fibroblasts are activated towards a myofibroblast state, express contractile fibres.51,52 Leading up to 
the following section of this review article, with further single-cell RNA-sequencing (scRNA-seq) data being generated 
from cardiovascular tissues and shared through data archives, we can hope that bioinformatic deduction of the relative 
contribution of cell types and sub types to bulk tissue expression changes will soon evolve in the cardiovascular field.  
                                               
4. Single-cell transcriptomic analysis  
The advent of scRNA-seq technology provides an unparalleled opportunity for high-resolution profiling of the global 
transcriptional signature of individual cells in models of disease and human tissue. Since the seminal report of 
transcriptome sequencing at the single cell level of a mouse blastomere a decade ago, there has been an early 
exponential rise in studies applying this technology in the cardiovascular system.53 ScRNA-seq permits us to catalogue 
the cellular composition of a tissue and to classify cell and transcriptional heterogeneity and plasticity under different 
conditions in an unbiased fashion. Therefore, scRNA-seq holds great promise as an accessible technology that can 
provide pivotal in-depth insight into the molecular regulators associated with CVD and regeneration.  
Analyses of bulk tissues produce signals that are an average across several cell-types in the tissue and so are unsuited 
to defining the role of individual cells. However, scRNA-seq allows the characterization of gene expression changes in 
individual cells and therefore an opportunity to deconvolve both cellular and disease-induced heterogeneities that 
serve biological functions. 
In the heart, several papers reporting single cell transcriptional profiling of cardiac lineages from adult mice have 
emerged over the past two years. In a landmark study, single cell transcriptomic was applied to map changing cell 
subpopulations in the healthy and injured mouse heart 3 days after ischaemia-reperfusion.54 This identified 
cytoskeleton-associated protein 4 (Ckap4) as a specific marker of activated CFs following injury. In another study, Forte 
and colleagues used scRNA-seq to characterise the dynamic transcriptional changes in non-CM cells at multiple 
timepoints following MI, identifying the occurrence of an early myofibroblast response as a predictor of cardiac 
rupture.55 A high-resolution single cell gene expression atlas of isolated mouse cardiac ECs defined 10 transcriptionally-










following ischemic injury, and provided a rich resource of targets with a potential role in vascular regeneration of the 
injured myocardium.56 Sex-dependent transcriptional differences in cardiac cell subtypes were also shown, which may 
provide fundamental insight into the molecular cues that underpin sexually dimorphic responses to cardiac injury.57 In 
the last year, studies have been published using single nuclear and cellular sequencing from cardiac tissue describing 
the transcriptional landscape and heterogeneity in different chambers of the heart and between sexes in the context 
of heath and heart failure (HF).58,59 ScRNA-Seq has also revealed the extent of immune system activation in a mouse 
model of pressure overload-induced HF.60 
Outside the heart in the peripheral vascular setting, a number of studies have reported scRNA-seq of cells in blood 
vessels, for example in healthy and atherosclerotic mouse tissue.38,61,62 This has characterised the transcriptional 
signatures of specific vascular lineages and subpopulations, including the molecular profiling of a potential 
endovascular progenitor cell, with a large cluster of ECs expressing clear mesenchyme-associated genes even in 
healthy aorta. Two independent relatively large-scale studies have used scRNA-seq to map the transcriptional 
landscape associated with pluripotent stem cell commitment to vascular lineages, with a focus on ECs.63,64 McCracken 
sequenced over 100,000 single cells at several time-points during the differentiation protocol to identify many 
previously unknown transcription factors that are activated upon commitment of pluripotent cells to the endothelial 
lineage.64 This knowledge may be key for future studies aiming to interrogate specific facets of vascular biology such 
as specification to distinct endothelial types, perhaps even organ-selective endothelial types.  
See and colleagues applied single nuclear sequencing technology (snSeq) to identify both coding and non-coding RNA 
targets in CMs isolated from the left ventricles of healthy and failing hearts in mice and humans.65 Core markers were 
defined, including non-coding RNAs, expressed by healthy CM subpopulations and common to both mice and humans. 
This study further characterised transcriptional heterogeneity in stressed CMs and identified lncRNA candidates, 
including Gas5 and Sghrt, as regulators of gene expression networks associated with CM proliferation.  
The application of single cell technology has highlighted dynamic transcriptional plasticity and heterogeneity, including 
classification of previously unreported or rare cell subpopulations. However, discrepancies are already apparent. For 
example, Farbehi et al. found widespread expression of Ckap4 across virtually all cardiac stromal populations in their 
analyses, dissimilar to the findings of Gladka and colleagues that Ckap4 was specific to injured and activated CFs.54,66 
This can likely be explained by technical and  methodological discrepancies such as differences in the number of cells 
sequenced, read depth per cell, thresholds applied to filter out background ‘noise’ and a lack of consensus over a 
standardised workflow and tools for analysis, as described in Figure 2. Great care must be taken when interpreting 
individual datasets following stand-alone analysis, and recent studies have emphasised the benefit of aligning multiple 
independent datasets using integrated bioinformatics pipelines, including from different species, as a means to 
identifying more robust and conserved targets.  Archiving of raw sequencing datasets in open-access repositories may 
help to promote reproducibility and reduce potential issues caused by technical and biological discrepancies. An 
overview of the pros and cons of scRNA-seq technology is displayed in Figure 3.  
Although several statistical frameworks exist for differential gene expression (DE) analysis for the bulk RNA-seq, 
methods for scRNA-seq are just emerging.67,68 The real challenge in sn/scRNA-seq DE analysis is to take into account 
particular characteristics of scRNA-seq which include, low library sizes, high noise levels and a large fraction of dropout 
events.69 In addition, the stochasticity of gene expression in cells, results in multimodality of gene expression across 
different cells.70 To address these challenges several single cell specific methods have been developed. One example 
is that of model-based analysis of single-cell transcriptomics (MAST), which proposes to develop a generalised linear 
model to take in to account bimodal distribution arisen as a result of either detectable transcripts or non-detectable 
genes that may have arisen because of stochastic dropout events.71 Although, MAST has been evaluated to be one of 
the best performing statistical frameworks for detecting DE genes for single-cell datasets, DE analysis of scRNA-seq 
data remains to be a challenge, as the tools developed for scRNA-seq either focus to model dropout events or 
multimodality but not both.70 
The fast-paced evolution of snRNA-seq technology, and emerging applications such as snSeq of frozen tissues, will 
undoubtedly continue to provide critical new insights into cardiovascular homeostasis and disease processes that then 










techniques based on tissue disaggregation, another emerging application of next generation sequencing  is that of 
spatial transcriptomics. This method is an expansion on in situ hybridization into an unbiased high throughput 
method to analyse the presence and abundance of transcripts in a two- or three-dimensional context in complex 
tissues. One such example, Tomo-Seq (RNA Tomography for Spatially Resolved Transcriptomics) is able to obtain a 
genome-wide gene expression signature with high spatial 2D resolution in a mouse model of myocardial infarct (MI) 
spanning from the infarcted area to the remote area to identify new regulators of cardiac remodelling as well as in a 
zebrafish model of cryoinjury to identify mediators of cardiac regeneration.72,73 Other newly-established methods 
include solid-phase bar-coded RNA capture and so-called 3D-Cardiomics from which a transcriptome map has been 
constructed from microdissections of the healthy mouse heart.74 One limitation to be noted is that, to eliminate 
genomic DNA incorporation into library construction, current methods for spatial transcriptomics rely on polyA 
capture and detect mature mRNA species only.  
 
5. RNA splicing and circular RNAs  
Most mRNAs and lncRNAs generated in mammalian cells are composed of exons separated by introns. Certain introns 
are spliced-out constitutively, but many splicing signals are not used by all cells nor in all circumstances, leading to 
alternative splicing (AS). AS allows expansion of the genome to generate a diverse array of functional RNA-transcripts 
from a single gene. Being estimated to occur in about 90% of human genes, AS greatly increases the coding potential 
of the genome.75 Of note, AS can generate not only different isoforms of the same protein, but also functional non-
coding RNAs. Another example of splicing is that of the aforementioned 3’- to 5’-back-splicing generating circRNA 
species.12 The circRNA landscape expressed in the human and mouse heart as well as in differentiating CMs has 
revealed a large proportion of gene loci form stable detectable circRNAs.76 The most abundant of these, circSlc8a1-1, 
was found to act as a miR-133a competing endogenous sponge and its inhibition in pre-clinical pressure overload 
models attenuated the pathological cardiac hypertrophic response.77 Outside of the heart, circ_Lrp6, a circRNA 
enriched in vascular smooth muscle cells, regulates miRNA-145 function through acting as a sponge in vascular smoth 
muscle cells.78 
It has been known for a long time that transcripts that are important for cardiac homeostasis and function can be 
aberrantly spliced in human heart disease, but the magnitude of mis-splicing events has only become evident in the 
past decade. Widespread use of microarrays and RNA-seq techniques has established a robust association of altered 
AS of pivotal cardiac genes, including many sarcomeric and ion channel genes, with cardiac hypertrophy, dilated 
cardiomyopathy (DCM), and HF.79,80 An outline for the workflow for analysing splice variants from RNA-seq data with 
examples of computational tools available for each step is shown in Figure 4. 
The first generation of transcriptomic analyses used exon-microarrays to identify splicing events and, more recently, 
RNA-seq has revealed the pervasiveness of AS in an unbiased manner.81,82 AS regulation is mediated by the interaction 
between cis-elements around the splicing site in both introns and exons, and trans-acting RNA-binding proteins (RBPs) 
that bind to specific cis-elements. RBPs are dynamically regulated with a variety of mechanisms and can promote or 
inhibit the splicing of a specific intron. A subset of RBPs regulating AS in the heart have been identified, including 
RBFOX-1 and -2, MBNL1 (muscleblind-like protein 1), CELF1 (CUGBP Elav-Like Family Member 1) and RBM-20 and -24 
(RNA Binding Motif Protein 20 and 24).75 Evidence of the importance of these RBPs for heart physio-pathology derives 
mostly from genetic engineering of mouse models and cell culture experiments. Indeed, so far, only mutations in 
RBM20 have been shown to be associated with cardiomyopathy.83 
RBM20 mutations cause an early-onset and clinically aggressive form of familial DCM, associated with aberrant 
inclusion of specific exons in the Titin (TTN) transcript.84 This, in turn, results in the expression of very large and 
compliant TTN isoforms affecting the physiological heart passive stiffness.84 
TTN is a very large multi-exon gene encoding many transcript variants regulated by still poorly understood AS events. 
Transcriptomic analysis of cardiac-specific knockout mice indicates that TTN is also one of the direct splicing targets of 
murine Rbm24.85 It remains an open question whether human RBM24 is a cardiomyopathy-associated gene, since no 










originating from TTN are also absent in RBM20 null mice.87 Another RBP, Quaking, also regulates the formation of TTN-
circRNAs, that are likely mediators of Quaking cardio-protective effects.88 
RBPs can engage in antagonistic actions, as observed for CELF1 and MBNL1. While CELF1 decreases during heart 
development, MBNL1 increases.89 Manipulation of these RBPs in the adult heart replicating their levels in the embryo 
results in reactivation of the embryonic splicing pattern.89 Indeed, re-expression of a foetal splice variant programme 
a phenomenon characterizing most cardiomyopathies.82 
  
In particular, in myotonic dystrophy type 1 (DM1), extensive AS changes result from the CUG-expansions in the 
DMPK gene characterizing the disease.90 These triplet-repeat RNAs accumulate in the nucleus, acting as molecular 
sponges and altering the function of MBNL, CELF1 and other splicing factors, leading to re-expression of foetal 
isoforms in adult tissues, including the myocardium. Accordingly, after respiratory failure, cardiac arrhythmias are 
the most common cause of death in DM1 patients.91  
Another mechanism of AS regulation is made possible by splicing occurring co-transcriptionally for most genes, 
allowing the interaction between the splicing and the RNA-synthesis machinery.92 Thus, AS can be affected by RNA 
transcription kinetics, as well as by chromatin modifications and structure. 
Many computational methods have been developed to analyse RNA-seq datasets at exon level. All these methods rely 
on reads spanning each exonic junction, to estimate an abundance ratio between the two spliced isoforms (exclusion 
and inclusion isoforms), followed by a statistical test to assess the significance of the observed difference in splicing. 
Although implemented with a variety of statistical frameworks, all available methods suffer from high uncertainty for 
the AS events sampled with low sequencing coverage. High sequencing depth is necessary to obtain a representative 
picture of the gene expression pattern at isoform-level. The situation may be even more critical for circRNAs: these 
RNA species are devoid of a 3’-end and published datasets deriving from poly-A positive RNA cannot be used for their 
detection.  
A further, so-called third generation sequencing technology, which may be beneficial in the identification of novel 
transcript isoforms, is that of long-read sequencing.  Such long-read sequencing technologies have been developed 
by, for example, Pacific Biosciences PacBio or Single-molecule, real-time (SMRT) sequencing and Oxford Nanopore 
Technologies (ONT) and are able to sequence full-length transcripts in excess of 10 kb in length. The advantages of 
long-read sequencing over classic short read include lower error rates in mapping, reduces amplification bias, easier 
accurate assembly of regions of the genome comprising repetitive sequences and de novo gene assembly for poorly 
annotated genomes and genes as well as valuation of copy number variants. This has been reviewed extensively 
previously.93 Long-read sequencing has proven an effective strategy to identify novel transcripts and super repeat 
regions in very large muscle structural genes such as TTN and Nebulin (NEB), the biological relevance of which in 
cardiac and skeletal muscle are yet to be determined.94 
Although there has been significant progress in the characterisation of isoform-level transcriptomics and the discovery 
of the regulatory aspects of AS networks, demonstration of the functional consequences of the expression of different 
isoforms of individual genes is still scarce. Therefore, understanding the physio-pathological relevance of AS is one of 
the biggest challenges of CVD functional genomics. 
 
6. Subcellular compartmentalisation of RNA 
Unequal cellular distribution is characteristic of the majority of RNA species. Concentrations of RNAs at specific 
locations is highly associated with their functionality. A prime example is the transport of mRNAs from their site of 
production, the nucleus, to the cytoplasm, where they are actively translated.95 Binding to ribosomes creates a 
microdomain enriched in mature mRNAs. In addition, subcellular concentrations of ribosome-bound mRNAs provide 
a means of controlling local protein production, allowing creation of functional protein gradients. In turn, localised 
protein translation regulates key cellular processes such as specification and differentiation. In the heart, Mbnl 
regulates mRNA localisation via binding to 3’UTRs of transcripts encoding membrane proteins, consistent with the 
Mbnl localisation at the periphery of the cell.89 In CMs, YB-1, a single-strand nucleic acid-binding protein that regulates 










intercalated disk, resulting in increased a-smooth muscle actin deposition in cardiac sarcomeres at this location. These 
examples suggest translation occurs at pre-specified sites to favour targeting of proteins at relevant locations.96 
MiRNA processing and maturation is an example of regulated changes in localisation. MiRNA genes are genomically 
encoded individually or as clusters, intergenically or intronically to protein-coding genes.5 Primary miRNA transcripts 
are synthesised in the nucleus, processed by Drosha, exported to the cytoplasm and cleaved by Dicer to produce 
mature miRNAs. Then, miRNAs are loaded in a silencing complex (RISC) together with Argonaute proteins. This allows 
pairing to and targeting mRNAs to silence expression. Most mature miRNAs demonstrate therefore cytoplasmic 
enrichment. Moreover, processing bodies (P-bodies) are cytosolic organelles, which are the primary sites of miRNAs 
activity. Interestingly, the RISC is required for maintaining P-body integrity.97 RISC is also associated with polysomes, 
suggesting that miRNA-mediated repression is initiated in the rough endoplasmic reticulum. Altogether, miRNAs are 
concentrated in the cytoplasm at specific foci, each representing a functional step in the silencing pathway leading to 
mRNA degradation. On the other hand, the miRNA-loaded RISC can shuttle back into the nucleus, where it can exert 
additional regulatory function on transcription and splicing in the nucleoplasm or even in the chromatin. Finally, 
mature miRNAs are also found in mitochondria.98 They originate from the cytoplasm, but can also derive from the 
mitochondrial genome. Their actions involve fine-tuning of various mitochondrial functions via regulating the 
expression of respiratory chain subunits, and thereby mitochondrial electron transport and oxidative phosphorylation. 
There is a further emerging role for Argonaute proteins in the formation of RNA-induced transcriptional activation 
(RITA) complexes in association with small activating RNAs (saRNAs). RITAs translocate into the nucleus to enhance 
gene expression. Description and understanding of endogenous saRNAs in cardiovascular disease are yet to be 
unveiled and there may be a potential to harness saRNA biology as a therapeutic strategy.99 
Molecular mechanisms controlling the correct targeting of lncRNAs to their ultimate site of action are intrinsic parts 
of their functionality. Nuclear-enriched lncRNAs are mainly involved in transcriptional and epigenetic regulation 
through cis- or trans- mechanisms, acting at their site of transcription or via travelling to remote locations in the 
genome respectively. A large number of lncRNAs are also exported to the cytoplasm. Visualisation of nuclear lncRNAs 
using RNA fluorescent in situ hybridisation identifies lncRNAs either in discrete nuclear foci or more homogeneously 
in the nucleoplasm. Foci of chromatin-bound lncRNAs reflect active lncRNAs transcription, lncRNAs that remain 
tethered to their own locus or accumulation at target loci, for instance through formation of RNA-DNA triplexes, a 
mechanism of lncRNA-mediated regulation of gene expression. Moreover, lncRNAs are observed in other 
compartments such as nuclear speckles and paraspeckles, organelles implicated in mRNA processing. In addition, 
lncRNAs can also be nuclear and cytoplasmic, or purely cytoplasmic.100 In this vein, lncRNAs that act as decoy for 
miRNAs in competing endogenous network are usually found in the cytoplasm, the site of miRNA-mediated post-
transcriptional regulation. This is also the case for lncRNAs directly interacting with mRNAs for controlling their stability 
and degradation.  
Surprisingly, despite the fact that lncRNAs are not translated, many lncRNAs are found associated with ribosomes in 
polysome profiling experiments. As mentioned previously, this might reflect a role for lncRNAs in translation regulation 
or micropeptide production.16,17 Last but not least, lncRNAs are found in exosomes suggesting a role for lncRNAs in 
cell-to-cell communication.101  
7. Peripheral blood 
Mechanistic studies support peripheral blood RNAs as regulators of CVD. Since peripheral blood is easily accessible, it 
is a promising source of biomarkers for personalised healthcare in areas with room for improved diagnosis and 
treatment (e.g. HF, myocarditis, valvular disease progression and cardiogenic shock). The first studies on circulating 
miRNAs in cardiovascular disease focused on their diagnostic potential. Plasma levels of miR-1a and miR-133a/b were 
among the first miRNAs identified to be upregulated in acute MI. Many subsequent studies postulated dynamic 
changes in peripheral blood miRNAs in different areas of CVD, systematically reviewed elsewhere.102 However, a lack 
of protocol standardisation, small sample sizes without validation cohorts and heterogeneous patient populations 
have sometimes led to inconsistent results.  
When considering studies with miRNAs in larger populations with independent validation, the largest body of evidence 










significantly in patients undergoing septal ablation for hypertrophy, suggesting a troponin-like biomarker 
potential.103,104 However, after adjusting for cardiac troponin T or clinical variables in independent studies, these 
miRNAs lost significant diagnostic or prognostic capabilities in patients with chest pain or acute coronary 
syndrome.105,106 Other miRNAs, e.g. endothelium-enriched miR-126, have consistently been shown to be related to 
platelet function making them suitable as candidates for the prediction of atherothrombotic events in primary or 
secondary prevention.107–109 
Besides miRNAs, the biomarker potential of mRNAs, lncRNAs and circRNAs was  investigated after a few landmark 
reports in stable coronary artery disease (CAD), acute MI and HF.14,110 Plasma levels of LIPCAR and whole blood levels 
of QSOX1 and the circRNA MICRA have been identified and replicated as novel prognostic markers of subsequent left 
ventricular dysfunction in patients with MI, independent from classical prognostic markers including NT-
proBNP.15,111,112 
Nevertheless, none of these RNAs has as yet been assessed in a large interventional clinical study to tailor therapies 
or improve patient outcome. Several considerations may explain the challenge to translate experimental findings from 
transcriptomic studies back to the bedside (Figure 5). These challenges include the timing of blood sampling (e.g. 
lifestyle-related time-of-day fluctuations as well as stage of disease onset and progression), selecting the appropriate 
sample type, sample handling prior to storage, RNA isolation strategy, RNA quality and correct downstream RNA 
expression measurement with appropriate normalisation. RNA degradation is a serious limitation of transcriptomic 
studies in peripheral blood samples. In a clinical setting, liquid biospecimen cannot always be extracted and stored 
optimally to preserve the blood transcriptome. To overcome this challenge and eliminate other pre-analytical 
variables, blood collection tubes containing RNA stabilizers have been developed. Even with these precautions, RNA 
integrity and potential genomic DNA contamination should be assessed before starting downstream applications. For 
cell-free RNA (e.g. in plasma or exosomes), no dedicated approach to minimise RNA degradation has been described. 
Heparin administration to the patient or in the sample may also result in spurious RNA expression results.26 Finally, 
the quantity of extracted RNA may also constitute a hurdle for transcriptomic analyses. The abundance of RNA 
transcripts can be very low in plasma, particularly lncRNAs and circRNAs, which tend to be relatively weakly expressed 
in blood compartments such as exosomes. However, the continuous improvement of sequencing and PCR 
technologies is facilitating reliable transcriptomic studies from very low amounts of starting material. The ligation-free 
CATS technology has been developed to prepare RNA-seq libraries from low input RNA down to 100 picograms.113 
Nonetheless, with these technologies, increased sensitivity might also be synonymous of increased sensitivity to 
detection of non-RNA species (e.g. circulating genomic DNA).114 A high-quality RNA is therefore necessary for 
transcriptomic studies from low input RNA isolated from a small volume of plasma/serum or exosomes. 
Only two RNA-based biomarkers in vitro diagnostic assays for cardiac conditions are commercially available. Corus® 
CAD (CardioDx, Palo Alto, CA, USA) uses whole blood RNA for the diagnosis of stable coronary artery disease in non-
diabetic patients and AlloMap® (CareDx, Brisbane, CA, USA) uses peripheral blood mononuclear cells for the detection 
of acute rejection in patients who underwent cardiac transplantation.115,116 Both tests have a high negative predictive 
value, and the latter is the only RNA test in cardiovascular disease that demonstrated effectiveness in a clinical trial.117 
 
8. Personalised Medicine / Tailored approaches  
As previously discussed, the revolution in deeper and faster clinical genetic and transcriptomic phenotyping is enabling 
us to understand disease-associated changes in each patient. This allows the opportunity for personalising therapeutic 
strategies.  
Transcriptome changes in the blood (cells or plasma) may help to better diagnose or determine the prognosis of our 
patients. Indeed, many clinical guidelines emphasise the unmet need for personalised medicine approaches. For 
instance, biomarker-guided cardiovascular therapy represents an interesting approach to identify the right patients, 
make accurate diagnostic decisions and monitor efficacy. NcRNA signatures provide valuable molecular insight of 
patient phenotypes and could add to traditional markers and established clinical variables.  
Short circulating miRNAs show promise for making predictions of cardiovascular patients; plasma miRNA-1254 levels 
predicted changes in left ventricular (LV) volumes and LV ejection fraction at 6 months after ST elevation myocardial 










deserves further investigation.118 LncRNA biomarkers are also being investigated as novel predictive tools to monitor 
therapeutic effectiveness and to stratify patients. The lncRNA SENCR blood levels before the start of pioglitazone 
therapy allowed distinction of responders from non-responders and was found to be a better predictor of the response 
to therapy than are other traditional clinical variables.119 Thus, assessment of lncRNA levels could constitute a major 
breakthrough in the development of personalised medicine to guide medical therapy, with important implications in 
terms of adverse effects and treatment costs. Another example demonstrating the potential of circulating miRNAs to 
predict the response to LVAD has been previously evaluated in patients with severe advanced HF. Morley-Smith et al. 
classified the clinical response to LVAD therapy based on NT-proBNP concentration at 3 months 105. Selected patients 
with a NT-proBNP above the 50th percentile were identified as ‘poor responders’ whereas patients below the 50th 
percentile as ’good responders’. By screening >1000 miRNAs, miR-1202 was found to be a useful biomarker to predict 
the response to LVAD therapy. Baseline circulating miR-1202 levels stratified the cohort into poor and good responders 
with greater sensitivity and specificity than baseline NT-proBNP. Thus, miR-1202 emerges as an interesting biomarker 
to select LVAD therapy or alternative interventions, such as urgent cardiac transplantation.120 
These examples illustrate that personalised medicine approaches show promise in becoming a reality in the near 
future. The rise of new technologies such as global and single cell sequencing, the use of artificial intelligence and 
machine learning concepts will lead to tremendous new discoveries and clinically useful applications and finally also 
to better and safer therapies (Figure 6).  
 
                    
9. Brief Conclusion 
Recent breakthroughs in deep-sequencing technology has enabled us to delineate transcriptomes, genomes and 
epigenomes from individual cells and cell types in complex heterogeneous organs and tissues of the CV system and 
unveil novel types, low or rarely expressed ncRNA transcripts. 
With the rapid speed and reduced costs of DNA and RNA-sequencing, we are now on the brink of being in a position 
to fully characterise each individual patient at the molecular level. To fully realise personalised medicine, we need to 
bridge interdisciplinary gaps to address the challenges posed by a deeper insight into the transcriptome regulation in 
the cardiovascular system, to create unity and standardisation of methodologies: from sample preparation to 
bioinformatics analysis to interventional studies, for ultimately translating the findings into high-impact outcomes for 
public health.  
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Figure Legends 
Figure 1: Depiction of the major cell types of the mature mammalian heart along with examples of ways cellular 
morphology and function can change in disease. Numbered arrows refer to the processes numbered in the text.  Text 
and numbering is colour-coded according to cell type. From far-right clockwise: Endothelial cells, Cardiomyocytes, 
Immune cells, Smooth muscle cells, Pericytes, Cardiac fibroblasts. 
Figure 2: Schematic of a typical scRNA-seq workflow: Single cells are separated and sequencing libraries generated 










reference genome to generate count matrices. Following quality control (QC) and normalisation, dimension reduction 
is performed to facilitate visualisation in low dimensional space. Subsequent clustering is performed to group cells by 
their similarity in transcriptional profile. Frequently used bioinformatic tools for each of these steps are indicated on 
the right side. 
Figure 3: Advantages (Pros) and Challenges (Cons) of single cell sequencing technology 
Figure 4: Schematic of typical alternative splicingAS analysis workflow ufromsing RNA-seq data. Frequently used 
bioinformatic tools for each are indicated on the right side of each step. 
Figure 5: Challenges and opportunities in transcriptomic studies in peripheral blood. 















Table 1: Pre-analytical variables in translational cardiovascular research 
Variable Applicability to Translational Cardiovascular research References 
1. Post-mortem interval 
 
The time between death and sample collection and appropriate 
storage.  
23–25 
2. Anti-coagulants The effects of anti-coagulants can present themselves in a 
number of ways in translational research. Many cardiovascular 
patients are administered drugs such as heparin or warfarin, 
which not only affects blood clotting but can also interfere with 
downstream molecular applications such as cDNA synthesis.  
Anti-coagulant agents including EDTA and citrate are also used in 
the preparation of plasma, serum or white blood cells. 
 
26,27 
3. Pre-processing interval The time between sample extraction and processing (in the case 
of plasma, serum or white blood cell isolation) or storage (e.g. 
freezing cardiac samples).  
28 
4. Processing method  The protocol used for extraction of plasma, serum or white blood 
cells isolation.  
 
5. Samples storage Receptacles for liquid biopsies and solid tissue can affect 
preservation of RNA and DNA (e.g. cryo-tubes pre-coated with 
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